Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters

Abstract

Background:

Anti-John Cunningham virus (JCV) serology has been studied with varying results concerning longitudinal changes.

Objectives and methods:

Results from 17 published natalizumab-treated multiple sclerosis (MS) patient cohorts were analyzed with common parameters and subsequently verified in two large independent cohorts with 722 and 499 patients from Germany and the United States.

Results:

Published studies and the verification showed (1) a mean of 10.80% sero-negative patients presented with sero-status change to positivity per year; (2) patients, who sero-convert to index values <0.9, convert from near the threshold and have a high probability of reverting with time; (3) patients, who convert to index values >0.9, start with low index values; (4) while JCV sero-positive patients with low index values sometimes revert to sero-negativity, patients with high index values almost never revert; and (5) the conversion rate of natalizumab-treated patients is three to four times higher than the biological conversion by age.

Conclusion:

JCV sero-conversion was comparable using standardized parameters and indicates influence of natalizumab on JCV immune control. Converters to low index values are probably consistently infected with JCV with varying low levels of activity, in line with their low risk to develop progressive multifocal leukoencephalopathy (PML). Patients with high index values rarely revert back to sero-negativity.

Keywords

Multiple sclerosis natalizumab JCV serology PML

Get full access to this article

View all access options for this article.

References

Zurhein

Chou

. Particles resembling papova viruses in human cerebral demyelinating disease. Science 1965; 148(3676): 1477–1479.

Astrom

Mancall

Richardson

. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain 1958; 81(1): 93–111.

Clifford

Nath

Cinque

et al . A study of mefloquine treatment for progressive multifocal leukoencephalopathy: Results and exploration of predictors of PML outcomes. J Neurovirol 2013; 19(4): 351–358.

Du Pasquier

Kuroda

Zheng

et al . A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127(Pt 9): 1970–1978.

Cinque

Bossolasco

Brambilla

et al . The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: Study of 43 cases with review of the literature. J Neurovirol 2003; 9(suppl. 1): 73–80.

Van Assche

Van Ranst

Sciot

et al . Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353(4): 362–368.

Kleinschmidt-DeMasters

Tyler

. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353(4): 369–374.

Langer-Gould

Atlas

Green

et al . Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353(4): 375–381.

Gorelik

Lerner

Bixler

et al . Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 2010; 68(3): 295–303.

10.

https://medinfo.biogenidec.com (accessed 4 November 2016).

11.

Schwab

Schneider-Hohendorf

Pignolet

et al . PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler 2016; 22(8): 1048–1060.

12.

Villar

Costa-Frossard

Masterman

et al . Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol 2015; 77(3): 447–457.

13.

Ontaneda

Fox

Gagne Brosseau

M-S

et al . Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay. Neurology 2016; 87(9): 957–958.

14.

Lee

Plavina

Castro

et al . A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013; 57(2): 141–146.

15.

Plavina

Subramanyam

Bloomgren

et al . Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76(6): 802–812.

16.

Randhawa

Zygmunt

Shapiro

et al . Viral regulatory region sequence variations in kidney tissue obtained from patients with BK virus nephropathy. Kidney Int 2003; 64(2): 743–747.

17.

Pastrana

Brennan

Cuburu

et al . Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathog 2012; 8(4): e1002650.

18.

Wollebo

White

Gordon

et al . Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 2015; 77(4): 560–570.

19.

Bozic

Richman

Plavina

et al . Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1. Ann Neurol 2011; 70(5): 742–750.

20.

Trampe

Hemmelmann

Stroet

et al . Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012; 78(22): 1736–1742.

21.

Olsson

Achiron

Alfredsson

et al . Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler 2013; 19(11): 1533–1538.

22.

Bozic

Subramanyam

Richman

et al . Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol 2014; 21(2): 299–304.

23.

Egli

Infanti

Dumoulin

et al . Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199(6): 837–846.

24.

Sroller

Hamšíková

Ludvíková

et al . Seroprevalence rates of BKV, JCV, and MCPyV polyomaviruses in the general Czech Republic population. J Med Virol 2014; 86(9): 1560–1568.

25.

Antonsson

Green

Mallitt

K-A

et al . Prevalence and stability of antibodies to the BK and JC polyomaviruses: A long-term longitudinal study of Australians. J Gen Virol 2010; 91(Pt 7): 1849–1853.

26.

Hennes

Kornek

Huppke

et al . Age-dependent seroprevalence of JCV antibody in children. Neuropediatrics 2016; 47(2): 112–114.

27.

Sundqvist

Buck

Warnke

et al . JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog 2014; 10(4): e1004084.

28.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2; Sawcer

Hellenthal

Pirinen

et al . Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476(7359): 214–219.

29.

Dominguez-Mozo

Rus

Santiago

et al . Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort. Eur J Clin Invest 2017; 47(2): 158–166.

30.

Havla

Kleiter

Kümpfel

. Bridging, switching or drug holidays – How to treat a patient who stops natalizumab? Ther Clin Risk Manag 2013; 9: 361–369.

31.

Alroughani

. High discontinuation rate of natalizumab in JC virus seropositive patients due to significant anxiety and safety feelings. Mult Scler 2014; 20(12): 1667–1668.

32.

PML incidence in patients receiving Tysabri (natalizumab). Biogen Idec, http://medinfo.biogenidec.com (accessed 4 November 2016).

33.

Kolasa

Hagman

Verkkoniemi-Ahola

et al . Anti-JC virus seroprevalence in a Finnish MS cohort. Acta Neurol Scand 2016; 133(5): 391–397.

34.

Dominguez-Mozo

Garcia-Montojo

Las Heras de

et al . Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab. J Neuroimmune Pharmacol 2013; 8(5): 1277–1286.

35.

Berger

Houff

Gurwell

et al . JC virus antibody status underestimates infection rates. Ann Neurol 2013; 74(1): 84–90.

36.

Campagnolo

Patel

et al . Four-year longitudinal index stability data from stratify-2 support the clinical utility of index for risk stratification of natalizumab-associated progressive multifocal leukoencephalopathy (P5.407). Neurology 2016; 87(2): E25–E25.

37.

Warnke

Olsson

Hartung

H-P

. PML: The dark side of immunotherapy in multiple sclerosis. Trends Pharmacol Sci 2015; 36(12): 799–801.

38.

Warnke

Ramanujam

Plavina

et al . Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry 2013; 84(11): 1199–1205.

39.

Kalincik

Brown

Robertson

et al . Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon β-1a. Mult Scler 2016; 22(3 suppl.): 828–883.

40.

Spelman

Kalincik

Jokubaitis

et al . Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurol Clin Pract 2016; 6(2): 102–115.

41.

Bargiela

Bianchi

Westover

et al . Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology 2017; 88(7): 677–684.

42.

Lanzillo

Liuzzi

Amato

et al . JC virus antibodies index on natalizumab treatment: Fluctuations and seroconversion. Mult Scler 2013; 19(11 suppl.): 474–558.

43.

Outteryck

Zéphir

Salleron

et al . JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler 2013; 20(7): 822–829.

44.

Raffel

Gafson

Malik

et al . Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler 2015; 21(14): 1833–1838.

45.

Delbue

Elia

Carloni

et al . JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients. J Neurovirol 2015; 21(6): 645–652.

46.

Alroughani

Akhtar

Ahmed

et al . JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study. J Neurol Sci 2016; 360: 61–65.

47.

Hoyt

Christensen

Metzger

et al . Anti-JCV antibody serostatus in a long-term natalizumab infusing population. Mult Scler 2016; 22(3 suppl.): 400–705.

48.

Schwab

Schneider-Hohendorf

Pignolet

et al . Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm 2016; 3(1): e195.

49.

Vennegoor

van Rossum

Leurs

et al . High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol 2016; 23(6): 1079–1085.

50.

Donovan

LaGanke

. An evaluation of the longitudinal stability of anti-JC virus (JCV) antibody levels in patients with multiple sclerosis (MS) (P3.093). Neurology 2016; 86(16 suppl.): 54–55.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.16 MB